Scott M DeWire
Overview
Explore the profile of Scott M DeWire including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
2319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nicoletti A, Kenny C, Khalil A, Pan Q, Ralph K, Ritchie J, et al.
J Pharmacol Exp Ther
. 2016 Jul;
359(1):37-44.
PMID: 27440419
Therapeutic agents antagonizing B-cell-activating factor/B-lymphocyte stimulator (BAFF/BLyS) are currently in clinical development for autoimmune diseases; belimumab is the first Food and Drug Administration-approved drug in more than 50 years for...
2.
Chen X, Pitis P, Liu G, Yuan C, Gotchev D, Cowan C, et al.
J Med Chem
. 2013 Sep;
56(20):8019-31.
PMID: 24063433
The concept of "ligand bias" at G protein coupled receptors has been introduced to describe ligands which preferentially stimulate one intracellular signaling pathway over another. There is growing interest in...
3.
DeWire S, Yamashita D, Rominger D, Liu G, Cowan C, Graczyk T, et al.
J Pharmacol Exp Ther
. 2013 Jan;
344(3):708-17.
PMID: 23300227
The concept of ligand bias at G protein-coupled receptors broadens the possibilities for agonist activities and provides the opportunity to develop safer, more selective therapeutics. Morphine pharmacology in β-arrestin-2 knockout...
4.
DeWire S, Violin J
Circ Res
. 2011 Jul;
109(2):205-16.
PMID: 21737816
Drug discovery efforts targeting G-protein-coupled receptors (GPCR) have been immensely successful in creating new cardiovascular medicines. Currently marketed GPCR drugs are broadly classified as either agonists that activate receptors or...
5.
Rajagopal S, Ahn S, Rominger D, Gowen-MacDonald W, Lam C, DeWire S, et al.
Mol Pharmacol
. 2011 May;
80(3):367-77.
PMID: 21610196
Seven transmembrane receptors (7TMRs), commonly referred to as G protein-coupled receptors, form a large part of the "druggable" genome. 7TMRs can signal through parallel pathways simultaneously, such as through heterotrimeric...
6.
Violin J, DeWire S, Yamashita D, Rominger D, Nguyen L, Schiller K, et al.
J Pharmacol Exp Ther
. 2010 Aug;
335(3):572-9.
PMID: 20801892
Biased G protein-coupled receptor ligands engage subsets of the receptor signals normally stimulated by unbiased agonists. However, it is unclear whether ligand bias can elicit differentiated pharmacology in vivo. Here,...
7.
Walters R, Shukla A, Kovacs J, Violin J, DeWire S, Lam C, et al.
J Clin Invest
. 2009 Apr;
119(5):1312-21.
PMID: 19349687
Nicotinic acid is one of the most effective agents for both lowering triglycerides and raising HDL. However, the side effect of cutaneous flushing severely limits patient compliance. As nicotinic acid...
8.
Kim J, Zhang L, Peppel K, Wu J, Zidar D, Brian L, et al.
Circ Res
. 2008 Jun;
103(1):70-9.
PMID: 18519945
Atherosclerosis and arterial injury-induced neointimal hyperplasia involve medial smooth muscle cell (SMC) proliferation and migration into the arterial intima. Because many 7-transmembrane and growth factor receptors promote atherosclerosis, we hypothesized...
9.
DeWire S, Kim J, Whalen E, Ahn S, Chen M, Lefkowitz R
J Biol Chem
. 2008 Feb;
283(16):10611-20.
PMID: 18276584
Seven transmembrane receptors (7TMRs) exert strong regulatory influences on virtually all physiological processes. Although it is historically assumed that heterotrimeric G proteins mediate these actions, there is a newer appreciation...
10.
Wisler J, DeWire S, Whalen E, Violin J, Drake M, Ahn S, et al.
Proc Natl Acad Sci U S A
. 2007 Oct;
104(42):16657-62.
PMID: 17925438
For many years, beta-adrenergic receptor antagonists (beta-blockers or betaAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction. More recently, beta-adrenergic receptor antagonists...